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Fig. 1. Suggested intermediate complex in the reaction between cysteine, p-chloromercuribenzoate and aurothiomalate
In an attempt to investigate this further, the simpler system of the interaction of aurothiomalate with cysteine was investigated.
Cysteine ( l o r n ) was treated with aurothiomalate ( l o r n ) at pH9-11. The extent of the reaction was monitored by measuring the precipitation of aurocysteine (by using either [195Au] aurothiomalate or ~-['~C]cysteine) after neutralization with HCI (C. J. Danpure, unpublished work). The ability of N-ethylmaleimide, p-chloromercuribenzoate andp-chIoromercuriphenylsulphonate (all l o r n ) to prevent the precipitation of aurocysteine on neutralization was determined. The results in Table l( b) show that, whereas Nethylmaleimide completely blocks the interaction, the organomercurials, p-chloromercuribenzoate and p-chloromercuriphenyIsulphonate, do not. In addition, aurothiomalate was able to block completely the reaction between cysteine and pchloromercuribenzoate.
When these results are compared with those obtained with albumin (Table la) , it can be Seen that in both cases, whereas the thiol-group-alkylating agent N-ethylmaleimide blocks the thiol group-aurothiomalate reaction, the organomercurials (e.g. p-chloromercuribenzoate) do not. However, the cysteine residue of albumin differs from cysteine in that in the former the aurothiomalate and p-chloromercuribenzoate may be bound together on the thiol group, whereas in the latter aurothiomalate appears to displace p-chloromercuribenzoate from the thiol group.
On the basis of these results it is suggested that an intermediate complex may exist (such as that in Fig. 1 ) in the reaction between cysteine, p-chloromercuribenzoate and aurothiomalate. Presumably this proves to be unstable in neutral solution owing to the low solubility of aurocysteine. On the other hand, in the ionic environment of the cysteine residue of albumin, the complex might be stabilized, allowing both p-chloromercuribenzoate and aurothiomalate to beeffectively bound to the same cysteine residue.
BIOCHEMICAL SOCIETY TRANSACTIONS binding site for DNA is located on the subunit (Zillig et al., 1970) , and the Bsubunit contains the binding site for the inhibitor rifampicin (Rabussay & Zillig, 1969; Stender et al., 1975 1974; Frischauf & Scheit, 1973) . Little is known of the role of the a subunits, although they do induce a conformation change in isolated B subunits (Lowe & Malcolm, 1976) .
Little is known of the amino acid side chains present at the initiation and elongation sites nor of their stereochernical relationship to each other.
We have used butanedione, which, in the presence of borate, modifies arginine side chains and inactivates RNA polymerase. The initial loss of activity is a pseudo-first-order reaction, and, since the first-order rate constant is proportional to butanedione concentration, it may be concluded that the group or groups involved in activity loss all react with the same rate constant.
The concentration-dependence of the protection afforded by ATP or GTP suggests that the arginine residue(s) being protected occur at the initiation site rather than the elongation site for RNA synthesis. This is consistent with the much lower degrees of protection produced by CTP or UTP, since these nucleotides do not bind to the initiation site (Wu & Goldthwait, 1969a,b) .
To investigate the relationship between the initiation site and the elongation site we have studied the interaction of the dye Cibacron F3G-A with the enzyme. This dye appears to bind to dinucleotide-binding sites in enzymes (Thompson et al., 1975) , and dinucleotides are capable of initiating RNA chains with RNA polymerase (Downey et al., 1971) . Cibacron is a powerful inhibitor of RNA polymerase with a Ki of the order of 5 PM. This is, however, several orders of magnitude weaker than its inhibition constant for lactate dehydrogenase, an enzyme known from crystallographic studies to contain a dinucleotide fold.
RNA polymerase binds to a column made by covalently linking Blue Dextran to Sepharose 4B [Pharmacia (G.B.), London W.5, U.K.]. The binding is sufficiently strong that 20m~-ATPor0.3 M-KCI isrequired toelutetheenzyme. However,forthoseenzymes that are known to possess a dinucleotide fold, elution is achieved by either less than 1OmM-ATP or by ~.OM-KCI. Thus on this evidence it cannot be concluded that RNA polymerase contains this element of super-secondary structure. RNA polymerase totally inhibited by rifarnpicin binds equally strongly to the Cibacron column. This shows that the two inhibitors bind at separate sites and also that the conformational change, which rifampicin is presumed to induce, does not significantly alter the Cibacron-binding site.
